{"drugs":["Reclast","Zoledronic Acid","Zometa"],"mono":{"0":{"id":"926501-s-0","title":"Generic Names","mono":"Zoledronic Acid"},"1":{"id":"926501-s-1","title":"Dosing and Indications","sub":[{"id":"926501-s-1-4","title":"Adult Dosing","mono":"<ul><li>safety and effectiveness of zoledronic acid for the treatment of osteoporosis are based on 3 years of data from clinical trials; the optimal duration of use has not been determined; all patients should be periodically evaluated for the need for continued therapy; patients at low risk of fractures should be evaluated for drug discontinuation after 3 to 5 years, and those who discontinue therapy should be monitored periodically for fracture risk<\/li><li><b>Bone metastasis - Solid tumor configuration:<\/b> 4 mg IV infused over 15 minutes every 3 to 4 weeks; administer with an oral calcium supplement of 500 mg and a multiple vitamin containing 400 international units of vitamin D<\/li><li><b>Hypercalcemia of malignancy:<\/b> 4 mg IV given as a single dose infusion over no less than 15 minutes; may repeat after a minimum of 7 days if serum calcium does not return to normal or remain normal after initial treatment<\/li><li><b>Multiple myeloma:<\/b> 4 mg IV infused over no less than 15 minutes every 3 to 4 weeks; administer with an oral calcium supplement of 500 mg and a multiple vitamin containing 400 international units of vitamin D<\/li><li><b>Osteopenia, Secondary to androgen-deprivation therapy in prostate cancer patients; Prophylaxis:<\/b> 4 mg IV infused over 15 minutes every 3 months<\/li><li><b>Osteoporosis, In men:<\/b> 5 mg IV infused over no less than 15 minutes every 1 year; when dietary intake of calcium and vitamin D is insufficient, adequate supplementation should be provided to reduce the risk of hypocalcemia; an average of 1200 mg\/day of calcium and 800 to 1000 international units\/day of vitamin D is recommended; acetaminophen 1000 mg or ibuprofen 400 mg ORALLY every 6 hours for 3 days beginning 4 hours after zoledronic acid infusion reduced the incidence of transient postdose influenza-like symptoms in a clinical trial<\/li><li><b>Osteoporosis, Secondary prophylaxis in patients with recent low-trauma hip fracture:<\/b> 5 mg IV infused over no less than 15 minutes every 1 year; individuals with insufficient dietary intake of calcium and vitamin D should be adequately supplemented to reduce the risk of hypocalcemia; postmenopausal women require an average of 1200 mg\/day of calcium and 800 to 1000 international units\/day of vitamin D; acetaminophen 1000 mg or ibuprofen 400 mg ORALLY every 6 hours for 3 days beginning 4 hours after zoledronic acid infusion reduced the incidence of transient postdose influenza-like symptoms in a clinical trial<\/li><li><b>Osteoporosis due to corticosteroids; Treatment and Prophylaxis:<\/b> 5 mg IV infused over no less than 15 minutes every 1 year; maintain adequate calcium and vitamin D; an average of 1200 mg\/day of calcium and 800 to 1000 international units\/day of vitamin D is recommended; acetaminophen 1000 mg or ibuprofen 400 mg ORALLY every 6 hours for 3 days beginning 4 hours after zoledronic acid infusion reduced the incidence of transient postdose influenza-like symptoms in a clinical trial<\/li><li><b>Paget's disease:<\/b> 5 mg IV as a single infusion infused over a period of at least 15 minutes; all patients should also receive 1500 mg elemental calcium daily in divided doses and 800 international units of vitamin D daily, particularly during the 2 weeks following administration; acetaminophen 1000 mg or ibuprofen 400 mg ORALLY every 6 hours for 3 days beginning 4 hours after zoledronic acid infusion reduced the incidence of transient postdose influenza-like symptoms in a clinical trial<\/li><li><b>Postmenopausal osteoporosis:<\/b> 5 mg IV infused over no less than 15 minutes every 1 year; in women with insufficient dietary intake of calcium and vitamin D, adequate supplementation should be provided to reduce the risk of hypocalcemia; postmenopausal women require an average of 1200 mg\/day of calcium and 800 to 1000 international units\/day of vitamin D; acetaminophen 1000 mg or ibuprofen 400 mg ORALLY every 6 hours for 3 days beginning 4 hours after zoledronic acid infusion reduced the incidence of transient postdose influenza-like symptoms in a clinical trial<\/li><li><b>Postmenopausal osteoporosis; Prophylaxis:<\/b> 5 mg IV infused over no less than 15 minutes once every 2 years; when dietary intake of calcium and vitamin D is insufficient, adequate supplementation should be provided to reduce the risk of hypocalcemia; an average of 1200 mg\/day of calcium and 800 to 1000 international units\/day of vitamin D is recommended; acetaminophen 1000 mg or ibuprofen 400 mg ORALLY every 6 hours for 3 days beginning 4 hours after zoledronic acid infusion reduced the incidence of transient postdose influenza-like symptoms in a clinical trial<\/li><\/ul>"},{"id":"926501-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Reclast(R) not indicated in pediatric patients<\/li><li>Zometa(R) not indicated in pediatric patients; should only be used in children with severe osteogenesis imperfecta if the potential benefit outweighs the risk<\/li><\/ul>"},{"id":"926501-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment (hypercalcemia of malignancy), mild to moderate (SCr less than 4.5 mg\/dL):<\/b> no dose adjustment required prior to initiation of therapy<\/li><li><b>renal impairment (multiple myeloma\/metastatic bone lesions from solid tumors):<\/b> 3.5 mg IV (baseline CrCl = 50 to 60 mL\/min); 3.3 mg IV (baseline CrCl = 40 to 49 mL\/min); or 3 mg IV (baseline CrCl = 30 to 39 mL\/min)<\/li><li><b>renal impairment (Paget disease or osteoporosis):<\/b> contraindicated in patients with CrCl less than 35 mL\/min or in patients with evidence of acute renal impairment; no dose adjustment required in patients with CrCl 35 mL\/min or greater<\/li><\/ul>"},{"id":"926501-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Bone metastasis - Solid tumor configuration<\/li><li>Hypercalcemia of malignancy<\/li><li>Multiple myeloma<\/li><li>Osteoporosis, In men<\/li><li>Osteoporosis, Secondary prophylaxis in patients with recent low-trauma hip fracture<\/li><li>Osteoporosis due to corticosteroids; Treatment and Prophylaxis<\/li><li>Paget's disease<\/li><li>Postmenopausal osteoporosis<\/li><li>Postmenopausal osteoporosis; Prophylaxis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Monoclonal gammopathy of uncertain significance, with osteopenia or osteoporosis<\/li><li>Osteopenia, Secondary to androgen-deprivation therapy in prostate cancer patients; Prophylaxis<\/li><li>Osteopenia, Secondary to hormone therapy in breast cancer patients; Prophylaxis<\/li><li>Osteopenia, Secondary to ovarian dysfunction induced by adjuvant chemotherapy in premenopausal women with early-stage breast cancer; Prophylaxis<\/li><\/ul>"}]},"3":{"id":"926501-s-3","title":"Contraindications\/Warnings","sub":[{"id":"926501-s-3-9","title":"Contraindications","mono":"<ul><li>CrCl less than 35 mL\/min; increased risk of renal failure<\/li><li>Hypersensitivity to zoledronic acid or any component of the product<\/li><li>Hypocalcemia<\/li><li>Renal impairment, acute; increased risk of renal failure<\/li><\/ul>"},{"id":"926501-s-3-10","title":"Precautions","mono":"<ul><li>Endocrine and Metabolic:<\/li><li>--Hypocalcemia has been reported, including severe cases involving cardiac arrhythmias and neurologic adverse events; increased risk with concomitant use of drugs known to cause hypocalcemia<\/li><li>-- Treatment of mineral metabolism disturbances (eg, hypocalcemia, hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine) before zoledronic acid initiation recommended, with ongoing monitoring<\/li><li>Immunologic:<\/li><li>-- Hypersensitivity reactions, including urticaria, angioedema, anaphylactic reaction or shock have been reported<\/li><li>Musculoskeletal:<\/li><li>-- Osteonecrosis of the jaw (ONJ) has been reported, especially with long-term treatment or concurrent use of drugs associated with ONJ; baseline oral assessment recommended in all patients, consider preventative dentistry measures in at-risk patients (eg, cancer, concomitant chemotherapy or steroid treatment, anemia, coagulopathy, poor oral hygiene, baseline dental disease or infection)<\/li><li>-- Atypical femoral shaft fractures (subtrochanteric and diaphyseal) have been reported with minimal or no trauma in patients taking bisphosphonates; consider treatment interruption if condition occurs<\/li><li>-- Musculoskeletal pain, severe and sometimes incapacitating, has been reported within 1 day to several months following therapy initiation; discontinue if severe symptoms occur<\/li><li>Renal:<\/li><li>-- Increased risk of renal toxicity with doses greater than 4 mg (Zometa(R)) or 5 mg (Reclast(R)) and infusion times less than 15 minutes; monitoring recommended<\/li><li>-- Renal impairment; increased risk of adverse reactions, especially renal deterioration; manage predisposing factors; monitoring recommended<\/li><li>-- Severe renal impairment; evaluate risks and benefits of treatment in patients with hypercalcemia of malignancy; use not recommended in patients with bone metastases<\/li><li>-- Multiple cycles of zoledronic acid or other bisphosphonates; increased risk for renal deterioration<\/li><li>-- Acute renal impairment, including renal failure, may occur, with life-threatening or fatal progression rarely reported; monitoring recommended for at-risk patients (ie, baseline moderate to severe renal impairment, renal compromise, older age, severe dehydration, or concurrent use of nephrotoxic agents or diuretics)<\/li><li>Respiratory:<\/li><li>-- Patients with aspirin-sensitive asthma have developed bronchoconstriction with bisphosphonate therapy<\/li><li>Other:<\/li><li>-- Elderly patients at increased risk for acute renal failure<\/li><li>-- Dehydration has occurred and may increase risk of renal deterioration; withhold treatment until adequate hydration  in patients with hypercalcemia of malignancy before administering; monitoring recommended<\/li><li>Concomitant Use:<\/li><li>-- Avoid concurrent use of Reclast(R) and Zometa(R), as both contain the same active ingredient<\/li><\/ul>"},{"id":"926501-s-3-11","title":"Pregnancy Category","mono":"<ul><li>D (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"926501-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"926501-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Peripheral edema (Paget disease, 3%; osteoporosis, 4.6% to 5.5%; osteopenia, 3.9% to 5.6%; hypercalcemia of malignancy, 5% to less than 10%; bone metastasis, 21%)<\/li><li><b>Endocrine metabolic:<\/b>Weight decreased (bone metastasis, 16%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (osteoporosis (female), 0.9% to 4.6%; osteoporosis (male), 7.9%; osteoporosis (male and female), 7.5%; osteopenia, 6.6% to 8.6%; Paget disease, 2%; hypercalcemia of malignancy, 16%; bone metastasis, 14%), Constipation (Paget disease, 6%; hypercalcemia of malignancy, 27%), Diarrhea (osteoporosis, 5.2% to 6%; osteopenia, 6.6% to 8.1%; Paget disease, 6%; hypercalcemia of malignancy, 17%; bone metastasis, 24%), Loss of appetite (osteoporosis, 1% to 2%; osteopenia, 0.6% to 2%; Paget disease, 2%; hypercalcemia of malignancy, 9%; bone metastasis, 22%), Nausea (osteoporosis (female), 4.5% to 8.5%; osteoporosis (male and female), 9.6%; osteopenia, 11.6% to 17.7%; Paget disease, 9%; hypercalcemia of malignancy, 29%; bone metastasis, 46%), Vomiting (Paget disease, 2%; osteoporosis, 3.4% to 4.6%; osteopenia, 5% to 7.6%; hypercalcemia of malignancy, 14%; bone metastasis, 32%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (Osteoporosis (female), 17.9% to 23.8%, (acute phase, 3% to 7%); osteoporosis (male, acute phase), 11.1%; osteopenia, 18.8% to 27.3%, (acute phase, 6.1%); hypercalcemia of malignancy, 5% to less than 10%; Paget disease, 9%; bone metastasis, 21%), Backache (Osteoporosis (male and female), 4.3%; osteoporosis (male, acute phase), 3.3%; osteopenia, 16.6% to 18.2%, (acute phase, 1.7%); Paget disease, 4%; bone metastasis, 15%), Pain in limb (Osteoporosis (female), 5.9% to 11.3%; osteoporosis (male and female), 3.1%; osteopenia, 11.1% to 16%, (acute phase, 3.9%); bone metastasis, 14%)<\/li><li><b>Neurologic:<\/b>Asthenia (osteoporosis, 3.2 to 5.3%; osteopenia, 2.8% to 6.1%; Paget disease, 2%; hypercalcemia of malignancy, 5% to less than 10%; bone metastasis, 24%), Dizziness (osteoporosis, 2% to 7.6%; osteopenia, 6.1% to 7.6%; Paget disease, 9%; bone metastasis, 18%), Headache (osteoporosis (female), 3.9% to 12.4%, (acute phase, 7%); osteoporosis (male), 15%, (acute phase, 9.8%); osteopenia, 14.6% to 20.4%, (acute phase, 13.3%); Paget disease, 11%; hypercalcemia of malignancy, 5% to less than 10%; bone metastasis, 19%), Insomnia (hypercalcemia of malignancy, 15%; bone metastasis, 16%), Paresthesia (Paget disease, 2%; bone metastasis, 15%.)<\/li><li><b>Renal:<\/b>Nephrotoxicity (bone metastasis, 11% to 17%)<\/li><li><b>Other:<\/b>Fatigue (osteoporosis (female), 2.1% to 5.4%; osteoporosis (male), 17.6%, (acute phase, 12.4%); osteopenia, 9.9% to 14.6%, (acute phase, 8.3%); Paget disease, 8%; bone metastasis, 39%), Fever (osteoporosis (female, acute phase), 7% to 18%; osteoporosis (male, acute phase), 15.7%; osteopenia, 21% to 21.7% (acute phase, 19.3%); Paget disease, 3% to 11%; hypercalcemia of malignancy (acute phase), 44%; bone metastasis, 32%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Atrial fibrillation (osteoporosis (female), 1.3% to 2.8%; osteoporosis (male), 3.3%; osteoporosis (male and female), 0.7%), Cardiac dysrhythmia<\/li><li><b>Dermatologic:<\/b>Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Endocrine metabolic:<\/b>Hypocalcemia (Osteoporosis, up to 0.2%; hypercalcemia of malignancy, 5% to less than 10%; bone metastasis, 1.3%; Paget disease, 3% to 21%)<\/li><li><b>Musculoskeletal:<\/b>Aseptic necrosis of bone of jaw, Bone pain (Osteoporosis (female), 3.2% to 5.8%; osteoporosis (male and female), 3.1%; osteopenia, 3.3% to 5.1%; Paget disease, 9%; hypercalcemia of malignancy, 12%; bone metastasis, 55%), Myalgia (Osteoporosis (female), 4.9% to 11.7%, (acute phase, 9%); osteoporosis (male), 19.6%, (acute phase, 17.1%); osteopenia, 19.2% to 22.7%; Paget disease, 7%; bone metastasis, 23%), Tetany<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident (osteoporosis, 2.3%), Numbness, Seizure<\/li><li><b>Renal:<\/b>Drug-induced renal failure, acute, Serum creatinine raised (osteoporosis, 1.2% to 2.1%; bone metastasis, 1%; hypercalcemia of malignancy, 2%)<\/li><li><b>Respiratory:<\/b>Dyspnea (Paget disease, 5%; osteoporosis (male), 6.5%; hypercalcemia of malignancy, 22%; bone metastasis, 27%)<\/li><\/ul>"},"6":{"id":"926501-s-6","title":"Drug Name Info","sub":{"0":{"id":"926501-s-6-17","title":"US Trade Names","mono":"<ul><li>Zometa<\/li><li>Reclast<\/li><\/ul>"},"2":{"id":"926501-s-6-19","title":"Class","mono":"<ul><li>Bisphosphonate<\/li><li>Calcium Regulator<\/li><\/ul>"},"3":{"id":"926501-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"926501-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"926501-s-7","title":"Mechanism Of Action","mono":" Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption. In vitro, zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis. Zoledronic acid also blocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone, including osteoclastic activity and skeletal calcium release induced by various stimulatory factors released by tumors.<br\/>"},"8":{"id":"926501-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"926501-s-8-24","title":"Distribution","mono":"Protein binding: 28% to 53% (in vitro) <br\/>"},"2":{"id":"926501-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic: none<\/li><li>Renal: none<\/li><\/ul>"},"3":{"id":"926501-s-8-26","title":"Excretion","mono":"Renal: 39 +\/- 16% unchanged <br\/>"},"4":{"id":"926501-s-8-27","title":"Elimination Half Life","mono":"146 hours <br\/>"}}},"9":{"id":"926501-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>patients should be adequately hydrated prior to administration<\/li><li>if previously refrigerated, allow solution to reach room temperature before administration<\/li><li>administer as a single-dose IV infusion in a vented line separate from other drugs; infuse over no less than 15 minutes, over a constant infusion rate<\/li><li>do not allow solution to come in contact with calcium-containing solutions or other divalent cation-containing infusion solutions (eg, LR)<\/li><li>Reclast(R), flush the IV line with 10 mL of NS after the infusion is completed<\/li><li>Zometa(R), dilute concentrate in 100 mL NS or D5W; ready-to-use solution may be administered directly to patient without further preparation<\/li><li>Zometa(R), single-use bottle, preparation of reduced doses requires removal\/discarding of zoledronic acid solution and replacement with NS or D5W; 3.5 mg dose requires 12 mL removed\/discarded\/replaced; 3.3 mg dose requires 18 mL removed\/discarded\/replaced; 3 mg dose requires 25 mL removed\/discarded\/replaced<\/li><li>Zometa(R), concentrate single-use vial, withdraw appropriate zoledronic acid volume and further dilute in 100 mL of NS or D5W; 4.4 mL for 3.5 mg dose; 4.1 mL for 3.3 mg dose; 3.8 mL for 3 mg dose<\/li><li>Zometa(R), diluted solution should be refrigerated at 2 to 8 degrees C (36 to 46 degrees F); do not exceed 24 hours from time of dilution to end of administration<\/li><\/ul>"},"10":{"id":"926501-s-10","title":"Monitoring","mono":"<ul><li>hypercalcemia of malignancy: normalization of serum calcium indicates efficacy<\/li><li>Paget's disease: normalization or reduction of serum alkaline phosphatase indicates efficacy<\/li><li>multiple myeloma or bone metastases from solid tumors: lack of skeletal-related events (pathologic fracture, radiation therapy or surgery to bone, spinal cord compression) suggests efficacy<\/li><li>osteoporosis: increase in bone mineral density of the lumbar spine and\/or hip indicates efficacy<\/li><li>Reclast(R): serum creatinine and CrCl (based on actual body weight using Crockcroft-Gault formula); before each dose in all patients and periodically in patients at risk for acute renal failure<\/li><li>Reclast(R): serum calcium, phosphorus, and magnesium prior to and during treatment in patients with preexisting hypocalcemia, those with disturbances of mineral metabolism (hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine)<\/li><li>Zometa(R): serum calcium; prior to initiating therapy<\/li><li>Zometa(R): serum creatinine; before each dose; additionally, renal function during therapy in all patients<\/li><li>Zometa(R): calcium, phosphate, and magnesium serum levels during therapy for hypercalcemia of malignancy  and multiple myeloma<\/li><li>electrolytes; regularly<\/li><li>hemoglobin and hematocrit; regularly<\/li><li>urine albumin; every 3 to 6 months<\/li><li>Reclast(R): fluid status; prior to each administration in the elderly and patients receiving concomitant diuretics<\/li><\/ul>"},"11":{"id":"926501-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Intravenous Powder for Solution: 4 MG<\/li><li>Intravenous Solution: 4 MG\/100 ML, 5 MG\/100 ML, 4 MG\/5 ML<\/li><\/ul><\/li><li><b>Novaplus Zoledronic Acid<\/b><br\/>Intravenous Solution: 5 MG\/100 ML, 4 MG\/5 ML<br\/><\/li><li><b>Reclast<\/b><br\/>Intravenous Solution: 5 MG\/100 ML<br\/><\/li><li><b>Zometa<\/b><br\/>Intravenous Solution: 4 MG\/100 ML, 4 MG\/5 ML<br\/><\/li><\/ul>"},"12":{"id":"926501-s-12","title":"Toxicology","sub":[{"id":"926501-s-12-31","title":"Clinical Effects","mono":"<b>BISPHOSPHONATES<\/b><br\/>USES: Bisphosphonates and have been used in the treatment of diseases associated with excessive bone turnover including osteoporosis, Paget's disease of bone, hypercalcemia of malignancy, and osteolytic bone lesions of multiple myeloma. PHARMACOLOGY: Bisphosphonates have a high affinity for mineralized bone and inhibit osteoclast-mediated bone resorption resulting in a net gain in bone mass. EPIDEMIOLOGY: Overdose of this medication is rare. MILD TO MODERATE TOXICITY: Mild to moderate toxicity of bisphosphonates have resulted in hypocalcemia, paresthesia, hypotension, fever, and vomiting. SEVERE TOXICITY: Acute renal failure and death have been reported following high dose administration of tiludronate (800 mg\/day IV for 2 days). ADVERSE EFFECTS: Dose-dependent upper gastrointestinal irritation (ie, esophagitis, esophageal ulcers, erosions, and dysphagia) is common. Asymptomatic decreases in calcium and phosphate may develop. Headache, musculoskeletal pain, and osteonecrosis of the jaw have been reported. Rare reports of rash and erythema have occurred.<br\/>"},{"id":"926501-s-12-32","title":"Treatment","mono":"<b>BISPHOSPHONATES <\/b><br\/><ul><li>Decontamination: Activated charcoal, gastric lavage<\/li><li>Hypocalcemia: 10 ml of 10% calcium gluconate or calcium chloride IV over 10-15 min; may be repeated.<\/li><li>Torsades de pointes: Correct electrolyte abnormalities.  Magnesium: Adult: 2 gm IV over 2 min, may repeat bolus, infusion 3 to 20 mg\/min. Child: 25-50 mg\/kg diluted 10 mg\/ml over 5-15 min. Isoproterenol, overdrive pacing.  Avoid procainamide, disopyramide, quinidine, sotalol<\/li><li>Monitoring of patient: ECG, continuous cardiac monitoring, calcium &amp; phosphate levels. CBC, electrolytes, renal function, fluid status if GI bleed suspected.  Test stool\/gastric aspirate for blood.<\/li><\/ul>"},{"id":"926501-s-12-33","title":"Range of Toxicity","mono":"<b>BISPHOSPHONATES<\/b><br\/>Therapeutic dose varies by agent. In general, overdose with these agents can result in clinically significant hypocalcemia, hypophosphatemia, and hypomagnesemia. <br\/>"}]},"13":{"id":"926501-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should inform healthcare professional of use of this drug prior to invasive dental procedure, as procedure may need to be postponed.<\/li><li>Drug may cause anemia, nausea, vomiting, constipation, diarrhea, fatigue, pyrexia, dyspnea, flu-like symptoms, weakness, edema, anorexia, myalgia, arthralgia, dizziness, and headache.<\/li><li>Advise patient to report new dull or aching hip or thigh pain.<\/li><li>Advise patient to report incapacitating or severe bone, joint, and\/or muscle pain.<\/li><li>Advise patient to report persistent jaw or mouth pain and\/or a nonhealing mouth or jaw sore.<\/li><li>Instruct patient to drink at least 2 glasses of fluid, and to eat normally, prior to receiving the drug infusion.<\/li><\/ul>"}}}